Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
The Mountain Center, Espanola, NM, USA.
Public Health Rep. 2023 Nov-Dec;138(6):936-943. doi: 10.1177/00333549221143086. Epub 2023 Jan 12.
Treatment for hepatitis C virus (HCV) infection is highly effective; however, people who inject drugs (PWID), the population most affected by HCV, may encounter barriers to treatment. We examined the cascade of care for HCV infection among young adult PWID in northern New Mexico, to help identify gaps and opportunities for HCV treatment intervention.
Young adults (aged 18-29 y) who self-reported injection drug use in the past 90 days were tested for HCV antibodies (anti-HCV) and HCV RNA. We asked participants with detectable RNA to participate in an HCV education session, prior to a referral to a local health care provider for treatment follow-up, and to return for follow-up HCV testing quarterly for 1 year. We measured the cascade of care milestones ranging from the start of screening to achievement of sustained virologic response (SVR).
Among 238 participants, the median age was 26 years and 133 (55.9%) were men. Most (90.3%) identified as Hispanic. Of 109 RNA-positive participants included in the cascade of care assessment, 84 (77.1%) received their results, 82 (75.2%) participated in the HCV education session, 61 (56.0%) were linked to care through a medical appointment, 27 (24.8%) attended the HCV treatment appointment, 13 (11.9%) attended their follow-up appointment, 6 (5.5%) initiated treatment, 3 (2.8%) completed treatment, and 1 (0.9%) achieved SVR.
We observed a steeply declining level of engagement at each milestone step of the cascade of care after detection of HCV infection, resulting in a suboptimal level of HCV treatment and cure. Programs that can streamline testing and expand access to treatment from trusted health care providers are needed to improve the engagement of PWID in HCV treatment.
丙型肝炎病毒 (HCV) 感染的治疗非常有效;然而,受 HCV 影响最大的人群——吸毒者(PWID),在治疗过程中可能会遇到障碍。我们研究了新墨西哥州北部年轻成年 PWID 中 HCV 感染的治疗流程,以帮助确定 HCV 治疗干预的差距和机会。
在过去 90 天内自我报告有注射吸毒史的年轻成年人(18-29 岁)接受 HCV 抗体(抗-HCV)和 HCV RNA 检测。我们要求 RNA 可检测的参与者参加 HCV 教育课程,然后转介到当地医疗保健提供者处进行治疗随访,并在接下来的 1 年内每季度进行 HCV 随访检测。我们测量了从筛查开始到实现持续病毒学应答 (SVR) 的治疗流程各个里程碑的达标情况。
在 238 名参与者中,中位年龄为 26 岁,其中 133 人(55.9%)为男性。大多数(90.3%)为西班牙裔。在纳入治疗流程评估的 109 名 RNA 阳性参与者中,84 名(77.1%)收到了检测结果,82 名(75.2%)参加了 HCV 教育课程,61 名(56.0%)通过医疗预约与医疗服务建立联系,27 名(24.8%)参加了 HCV 治疗预约,13 名(11.9%)参加了随访预约,6 名(5.5%)开始治疗,3 名(2.8%)完成治疗,1 名(0.9%)实现 SVR。
我们观察到 HCV 感染检测后,治疗流程的每一个环节的参与度都呈急剧下降趋势,导致 HCV 治疗和治愈效果不佳。需要简化检测程序并扩大获得值得信赖的医疗服务提供者的治疗途径的项目,以提高 PWID 参与 HCV 治疗的积极性。